187 related articles for article (PubMed ID: 32859533)
21. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of epithelial ovarian cancer treated at a tertiary-level hospital in India.
Chandy RG; Thomas V; Sebastian A; Mani T; Thomas A; Joel A; Ram TS; Peedicayil A
Indian J Cancer; 2023 Oct; 60(4):475-485. PubMed ID: 38185864
[TBL] [Abstract][Full Text] [Related]
23. Neo-adjuvant chemotherapy does not reduce surgical complexity nor the accuracy of intra-operative visual assessment of disease in advanced ovarian cancer.
Addley S; McGowan M; Crossland H; Johnson A; Asher V; Bali A; Abdul S; Phillips A
Eur J Surg Oncol; 2023 Nov; 49(11):107078. PubMed ID: 37804584
[TBL] [Abstract][Full Text] [Related]
24. MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.
Uwins C; Assalaarachchi H; Bennett K; Read J; Tailor A; Crawshaw J; Chatterjee J; Ellis P; Skene SS; Michael A; Butler-Manuel S
Int J Gynecol Cancer; 2024 Jun; 34(6):886-897. PubMed ID: 38561194
[TBL] [Abstract][Full Text] [Related]
25. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.
Nasioudis D; Wang X; Dhillon G; Latif N; Ko EM; Giuntoli RL; Gershenson D; Fader A; Carey M; Simpkins F
Int J Gynecol Cancer; 2023 Dec; 33(12):1906-1912. PubMed ID: 37879909
[TBL] [Abstract][Full Text] [Related]
26. Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer.
Saner FAM; Ruggeri G; Siegenthaler F; Wampfler J; Imboden S; Mueller MD
Int J Gynecol Cancer; 2023 Oct; 33(10):1595-1601. PubMed ID: 37567597
[TBL] [Abstract][Full Text] [Related]
27. Prediction of the survival of patients with advanced-stage ovarian cancer patients undergoing interval cytoreduction with the use of computed tomography reevaluation after neoadjuvant chemotherapy.
Li JY; Wang R
J Obstet Gynaecol Res; 2023 Nov; 49(11):2700-2710. PubMed ID: 37528642
[TBL] [Abstract][Full Text] [Related]
28. Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.
Cole AL; Austin AE; Hickson RP; Dixon MS; Barber EL
Cancer Epidemiol; 2018 Aug; 55():8-16. PubMed ID: 29758492
[TBL] [Abstract][Full Text] [Related]
29. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
30. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Ehmann S; Shay K; Zhou Q; Iasonos A; Sonoda Y; Gardner GJ; Long Roche K; Zammarrelli WA; Yeoushoua E; O'Cearbhaill RE; Zivanovic O; Chi DS
Gynecol Oncol; 2023 Feb; 169():118-124. PubMed ID: 36565685
[TBL] [Abstract][Full Text] [Related]
32. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
Barber EL; Rossi EC; Gehrig PA
Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS
Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis.
Tzanis AA; Iavazzo C; Hadjivasilis A; Tsouvali H; Antoniou GΑ; Antoniou SA
Oncol Rev; 2022; 16():10605. PubMed ID: 36531160
[No Abstract] [Full Text] [Related]
35. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
36. Association between BMI and oncologic outcomes in epithelial ovarian cancer: a predictors-matched case-control study.
Levin G; Brezinov Y; Tzur Y; Bar-Noy T; Brodeur MN; Salvador S; Lau S; Gotlieb W
Arch Gynecol Obstet; 2024 Jul; 310(1):587-593. PubMed ID: 38714562
[TBL] [Abstract][Full Text] [Related]
37. Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer.
Cai Y; Shu T; Zheng H
BMC Womens Health; 2024 Feb; 24(1):100. PubMed ID: 38326784
[TBL] [Abstract][Full Text] [Related]
38. Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer.
Tsibulak I; Fotopoulou C
Int J Gynecol Cancer; 2023 Oct; 33(10):1627-1632. PubMed ID: 37553165
[TBL] [Abstract][Full Text] [Related]
39. Days alive and out of hospital after surgical treatment of epithelial ovarian cancer: A Danish nationwide cohort study.
Ekmann-Gade AW; Høgdall C; Seibæk L; Noer MC; Rasmussen A; Schnack TH
Eur J Surg Oncol; 2023 Oct; 49(10):107039. PubMed ID: 37639861
[TBL] [Abstract][Full Text] [Related]
40. Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.
Lin JJ; Egorova N; Franco R; Prasad-Hayes M; Bickell NA
Obstet Gynecol; 2016 Jan; 127(1):81-89. PubMed ID: 26646132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]